Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia

Pharmacotherapy

Volumn 22, Issue 3 II, 2002, Pages 395-399

  Kays, Michael B ^a   Smith, David W ^a   Wack, Matthew F ^a   Denys, Gerald A ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFPROZIL; CEFTRIAXONE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PHENYLALANINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; TROVAFLOXACIN;

ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL MUTATION; CASE REPORT; CROSS RESISTANCE; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RESPIRATORY TRACT INFECTION; SEQUENCE ANALYSIS; SHORT SURVEY; STREPTOCOCCUS PNEUMONIA; TREATMENT FAILURE;

EID: 0036195137     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.5.395.33185     Document Type: Short Survey

References (29)

1. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study
2. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
3. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
4. Evolving resistance patterns of Streptococcus pneumoniae: A link with long-acting macrolide consumption?
5. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assessment
6. Streptococcus pneumoniae in the USA: In vitro susceptibility and pharmacodynamic analysis
7. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones"
8. Practice guidelines for the management of community-acquired pneumonia in adults
9. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention
10. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
11. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
12. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: Significant trends from the SENTRY antimicrobial surveillance program (North America, 1997-1999)
13. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
14. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program
15. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-Year longitudinal analysis
16. Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana
17. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae
18. Three levofloxacin treatment failures of pneumococcal respiratory tract infections [abstr]
19. Levofloxacin treatment failure of pneumococcal pneumonia and development of resistance during therapy
20. Levofloxacin failure in a patient with pneumococcal pneumonia
21. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae
22. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae working group
23. DNA gyrase, topoisomerase IV, and the 4-quinolones
24. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance
25. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates, including those with mutations in the gyrA, parC, and parE loci
26. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
27. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
28. New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones
29. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study